Prostate Cancer: Surgery with Darolutamide

We are studying whether adding darolutamide before and after surgery helps improve survival and quality of life for patients with high-risk or locally advanced prostate cancer.

>2 years≤5 visitsEfficacy phase (II)No PlaceboInvestigational MedicinesOralOncologyUrology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Darolutamide
Darolutamide is a substance that blocks male hormones' effects to help treat prostate cancer.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Bay 1841788

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Capio La Croix Du Sud
Urology
Balma, France
Centre Hospitalier Universitaire De Bordeaux
Urology
Bordeaux, France
Institut Bergonie
Urology
Bordeaux, France
Sponsor: Oncopole Claudius Regaud
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.